Form 4: Amphastar Pharmaceuticals Director Gayle Deflin Receives Significant Equity Grant

Amphastar Pharmaceuticals, Inc. Director Gayle Deflin was granted 5,122 restricted stock units and options to purchase 11,402 shares of common stock, aligning her interests with shareholders.

Summary

• Amphastar Pharmaceuticals, Inc. Director Gayle Deflin acquired 5,122 shares of common stock in the form of restricted stock units (RSUs) on June 2, 2025.
• These RSUs were granted at a price of $0 and are scheduled to vest on June 2, 2026.
• Additionally, Ms. Deflin was granted options to purchase 11,402 shares of common stock at an exercise price of $25.38 per share on June 2, 2025.
• These stock options also vest on June 2, 2026, and have an expiration date of June 2, 2035.
• Following these transactions, Ms. Deflin beneficially owns 10,914 shares of common stock and 11,402 stock options directly.
• The filing indicates that the transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director receiving equity grants aligns their interests with shareholders and is a standard practice for incentivizing long-term performance. It does not indicate any negative operational or financial news.

Positives

• The acquisition of restricted stock units and stock options by a director indicates a strong alignment of management's interests with those of shareholders, as their compensation is tied to the company's future performance.
• The grant of equity compensation is a standard practice for retaining and incentivizing key personnel, including directors.

Future Outlook

The future outlook indicates that the granted restricted stock units and stock options will vest on June 2, 2026, leading to an increase in the director's direct beneficial ownership of Amphastar Pharmaceuticals common stock and exercisable options.

Industry Context

This equity grant is consistent with common executive and director compensation practices across the pharmaceutical and broader corporate sectors, where stock-based incentives are used to align the interests of leadership with long-term shareholder value creation.

Comparison to Industry Standards

• While the specific value of the grant is unique to Amphastar Pharmaceuticals, the structure of granting restricted stock units and stock options with a vesting period is a standard compensation mechanism widely adopted by public companies, including peers like Teva Pharmaceutical Industries Ltd. or Mylan N.V. (now Viatris Inc.), to incentivize long-term performance and retention.
• The use of a Rule 10b5-1(c) plan for the transaction is also a common practice for insiders to manage their equity holdings in compliance with insider trading regulations, seen across various industries and companies of similar market capitalization.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: While not directly impacting all employees, such compensation practices can set a precedent for performance-based incentives within the company.
• Director (Gayle Deflin): Directly benefits from increased equity ownership and potential future gains tied to the company's stock price.

Next Steps

• The restricted stock units and stock options granted to Director Gayle Deflin are scheduled to vest on June 2, 2026.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership